Status:
COMPLETED
Body PSOriasis: Long-term Relapse CONTROL
Lead Sponsor:
LEO Pharma
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18+ years
Brief Summary
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian de...
Eligibility Criteria
Inclusion
- Patients planned to receive topical treatment of any kind to prevent relapse of symptoms
- Written informed consent
Exclusion
- Contraindications to selected treatment
- Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or phototherapy
Key Trial Info
Start Date :
June 11 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2020
Estimated Enrollment :
764 Patients enrolled
Trial Details
Trial ID
NCT03402828
Start Date
June 11 2018
End Date
May 15 2020
Last Update
March 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The State Autonomous Foundation of Public Health "Republic Clinical Dermatovenereological Dispensary" of the Republic of Tatarstan
Kazan', Tatarstan Republic, Russia, 420012